Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma

Modern Pathology

Volumn 22, Issue 10, 2009, Pages 1367-1378

  Lázár, Viktória ^a   Ecsedi, Szilvia ^a   Szöllsi, Attila G ^b   Tóth, Réka ^a   Vízkeleti, Laura ^a   Rákosy, Zsuzsa ^a,c   Bégány, Agnes ^b   Dány, Róza ^a,c   Balázs, Margit ^a,c  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

11q13 amplicon core; BRAF; CCND1 gene amplification; Melanoma; NRAS; TAOS

Indexed keywords

B RAF KINASE; CYCLIN D1; EMS1; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 3; FIBROBLAST GROWTH FACTOR 4; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE; UNCLASSIFIED DRUG;

ADULT; AMPLICON; ARTICLE; CHROMOSOME 11Q; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE AMPLIFICATION; GENE LOCATION; GENE MUTATION; GENE NUMBER; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MUTATION RATE; ONCOGENE N RAS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TAOS1 GENE;

ADULT; CHROMOSOMES, HUMAN, PAIR 11; CORTACTIN; CYCLIN D1; FEMALE; FIBROBLAST GROWTH FACTOR 3; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTORS; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; GENETIC ASSOCIATION STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; REPRODUCIBILITY OF RESULTS; SKIN NEOPLASMS; YOUNG ADULT;

EID: 70349655707     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.109     Document Type: Article

References (49)

1. Rodolfo M, Daniotti M, Vallacchi V. Genetic progression of metastatic melanoma. Cancer Lett 2004;214: 133-147.
2. Balazs M, Adam Z, Treszl A, et al. Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization. Cytometry 2001;46:222-232.
3. Bastian BC, LeBoit PE, Hamm H, et al. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 1998;58:2170-2175.
4. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-2147.
5. Yurakh AO, Ramos D, Calabuig-Farinas S, et al. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur Urol 2006;50:506-515; discussion 15.
6. Akervall J, Borg A, Dictor M, et al. Chromosomal translocations involving 11q13 contribute to cyclin D1 overexpression in squamous cell carcinoma of the head and neck. Int J Oncol 2002;20:45-52.
7. Elsheikh S, Green AR, Aleskandarany MA, et al. CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res Treat 2008;109:325-335.
8. Rodrigo JP, Garcia LA, Ramos S, et al. EMS1 gene amplification correlates with poor prognosis in squamous cell carcinomas of the head and neck. Clin Cancer Res 2000;6:3177-3182.
9. Komatsu Y, Hibi K, Kodera Y, et al. TAOS1, a novel marker for advanced esophageal squamous cell carcinoma. Anticancer Res 2006;26:2029-2032. (Pubitemid 43989465)
10. Xia J, Chen Q, Li B, et al. Amplifications of TAOS1 and EMS1 genes in oral carcinogenesis: association with clinicopathological features. Oral Oncol 2007; 43:508-514.
11. Schuuring E. The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes-a review. Gene 1995;159:83-96.
12. Zaharieva BM, Simon R, Diener PA, et al. Highthroughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. J Pathol 2003;201:603-608.
13. Huang X, Gollin SM, Raja S, et al. High-resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells. Proc Natl Acad Sci USA 2002;99: 11369-11374.
14. Filmus J, Robles AI, Shi W, et al. Induction of cyclin D1 overexpression by activated ras. Oncogene 1994;9: 3627-3633.
15. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-1512.
16. Sauter ER, Yeo UC, von Stemm A, et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 2002;62:3200-3206.
17. Utikal J, Udart M, Leiter U, et al. Additional Cyclin D(1) gene copies associated with chromosome 11 aberrations in cutaneous malignant melanoma. Int J Oncol 2005;26:597-605.
18. Patel AS, Schechter GL, Wasilenko WJ, et al. Overexpression of EMS1/cortactin in NIH3T3 fibroblasts causes increased cell motility and invasion in vitro. Oncogene 1998;16:3227-3232.
19. Wu H, Parsons JT. Cortactin, an 80/85-kilodalton pp60src substrate, is a filamentous actin-binding protein enriched in the cell cortex. J Cell Biol 1993;120:1417-1426.
20. Pasello G, Agata S, Bonaldi L, et al. DNA copy number alterations correlate with survival of esophageal adenocarcinoma patients. Mod Pathol 2009;22: 58-65.
21. Timpson P, Wilson AS, Lehrbach GM, et al. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. Cancer Res 2007;167:9304-9314.
22. Bringuier PP, Tamimi Y, Schuuring E, et al. Expression of cyclin D1 and EMS1 in bladder tumours; relationship with chromosome 11q13 amplification. Oncogene 1996;12:1747-1753.
23. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-954.
24. Omholt K, Karsberg S, Platz A, et al. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res 2002;8:3468-3474.
25. Sebolt-Leopold JS, Herrera R. Targeting the mitogenactivated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-947.
26. Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008;105:3041-3046.
27. King AJ, Patrick DR, Batorsky RS, et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res 2006;66:11100-11105.
28. Smalley KS, Flaherty KT. Integrating BRAF/MEK inhibitors into combination therapy for melanoma. Br J Cancer 2009;100:431-435.
29. Rousseau Jr DL, Gershenwald JE. The new staging system for cutaneous melanoma in the era of lymphatic mapping. Semin Oncol 2004;31:415-425.
30. Rakosy Z, Vizkeleti L, Ecsedi S, et al. EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis. Int J Cancer 2007;121:1729-1737.
31. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 2003;31:3406-3415.
32. Pattyn F, Speleman F, De Paepe A, et al. RTPrimerDB: the real-time PCR primer and probe database. Nucleic Acids Res 2003;31:122-123.
33. De Preter K, Speleman F, Combaret V, et al. Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay. Mod Pathol 2002;15:159-166.
34. Pfaffl MW, Georgieva TM, Georgiev IP, et al. Real-time RT-PCR quantification of insulin-like growth factor (IGF)-1, IGF-1 receptor, IGF-2, IGF-2 receptor, insulin receptor, growth hormone receptor, IGF-binding proteins 1, 2 and 3 in the bovine species. Domest Anim Endocrinol 2002;22:91-102.
35. Hoebeeck J, Speleman F, Vandesompele J. Real-time quantitative PCR as an alternative to Southern blot or fluorescence in situ hybridization for detection of gene copy number changes. Methods Mol Biol 2007;353: 205-226.
36. Hoebeeck J, van der Luijt R, Poppe B, et al. Rapid detection of VHL exon deletions using real-time quantitative PCR. Lab Invest 2005;85:24-33.
37. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
38. Kindich R, Florl AR, Jung V, et al. Application of a modified real-time PCR technique for relative gene copy number quantification to the determination of the relationship between NKX3.1 loss and MYC gain in prostate cancer. Clin Chem 2005;51:649-652.
39. Schmittgen TD, Zakrajsek BA, Mills AG, et al. Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Anal Biochem 2000;285: 194-204.
40. Smith CJ, Nedwell DB, Dong LF, et al. Evaluation of quantitative polymerase chain reaction-based approaches for determining gene copy and gene transcript numbers in environmental samples. Environ Microbiol 2006;8:804-815.
41. Dionisi HM, Harms G, Layton AC, et al. Power analysis for real-time PCR quantification of genes in activated sludge and analysis of the variability introduced by DNA extraction. Appl Environ Microbiol 2003;69: 6597-6604.
42. Murphy RM, Watt KK, Cameron-Smith D, et al. Effects of creatine supplementation on housekeeping genes in human skeletal muscle using real-time RT-PCR. Physiol Genomics 2003;12:163-174.
43. Bastian BC. Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer. Oncogene 2003;22:3081-3086.
44. Hay R, MacRae E, Barber D, et al. BRAF mutations in melanocytic lesions and papillary thyroid carcinoma samples identified using melting curve analysis of polymerase chain reaction products. Arch Pathol Lab Med 2007;131:1361-1367.
45. Poynter JN, Elder JT, Fullen DR, et al. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 2006;16:267-273.
46. Thomas NE, Edmiston SN, Alexander A, et al. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev 2007;16:991-997.
47. van Elsas A, Zerp SF, van der Flier S, et al. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 1996;149:883-893.
48. Omholt K, Platz A, Kanter L, et al. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003;9:6483-6488.
49. Smalley KS, Lioni M, Dalla Palma M, et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 2008;7:2876-2883.